-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022
HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022
Southlake, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today announced that Andrew Simpson, Chief Executive Officer of HeartSciences, will be participating at the at the 11th Annual Benchmark Discovery One-on-One Investor Conference which is being held on December 1, 2022, at the New York Athletic Club in New York City.
Mr. Simpson will take part in one-on-one meetings with institutional analysts and investors throughout the conference. The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format.
To schedule a one-on-one meeting with Mr. Simpson you may submit your request online via the link provided upon registration. To register for the conference, please visit .
About The Benchmark Company
The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in New York City. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm's sales, trading and equity research capabilities. For more information, please visit
About HeartSciences
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical usefulness. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® device and consumables for each test, is expected to be "razor-razorblade" as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed.
For more information, please visit: Twitter: @HeartSciences
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
For investor and media inquiries, please contact:
Investor Relations:
Crescendo Communications, LLC
Phone: (212) 671-1021
Email: HSCS@crescendo-ir.com
Company:
Gene Gephart
Phone: +1-737-414-9213 (US)
Email: investorrelations@heartsciences.com
Southlake, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today announced that Andrew Simpson, Chief Executive Officer of HeartSciences, will be participating at the at the 11th Annual Benchmark Discovery One-on-One Investor Conference which is being held on December 1, 2022, at the New York Athletic Club in New York City.
德克萨斯州南湖,2022年11月21日(环球通讯社)心脏测试实验室公司 D/b/a心脏科学(纳斯达克:HSC;HSCSW)(“心脏科学”或“公司”),一家专注于通过使用人工智能使心电(也称为EKG)成为更有价值的筛查工具来拯救生命的医疗技术公司,今天宣布,HeartSciences首席执行官Andrew Simpson将参加2022年12月1日在纽约体育俱乐部举行的第11届年度Benchmark Discovery一对一投资者大会。
Mr. Simpson will take part in one-on-one meetings with institutional analysts and investors throughout the conference. The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format.
在整个会议期间,辛普森将参加与机构分析师和投资者的一对一会议。该会议以独特的一对一形式为新兴的成长型和有活力的上市公司提供了接触机构和个人投资者的机会。
To schedule a one-on-one meeting with Mr. Simpson you may submit your request online via the link provided upon registration. To register for the conference, please visit .
要安排与辛普森先生的一对一会面,您可以通过注册时提供的链接在线提交您的请求。要注册参加会议,请访问.
About The Benchmark Company
关于基准公司
The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in New York City. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm's sales, trading and equity research capabilities. For more information, please visit
The Benchmark Company是一家专注于机构、研究驱动、销售交易和投资银行业务的公司。我们成立于1988年,总部设在纽约市。我们的重点是通过筹集资金、提供战略咨询服务、产生有洞察力的研究,以及通过利用公司的销售、交易和股票研究能力发展机构赞助来促进我们的企业客户的长期成功。欲了解更多信息,请访问
About HeartSciences
关于心脏科学
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical usefulness. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® device and consumables for each test, is expected to be "razor-razorblade" as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed.
For more information, please visit: Twitter: @HeartSciences
心脏测试实验室,Inc.d/b/a HeartSciences是一家医疗技术公司,专注于将基于人工智能的创新技术应用于心电(也称为EKG),以扩大和提高心电的临床用途。该公司的目标是通过使心电成为一种更有价值的心脏筛查工具来改善医疗保健,特别是在一线或护理点临床环境中。心脏科学公司的第一款获得美国食品和药物管理局批准的产品MyoVista®WaveCG,或称MyoVista®,是一种静止的12导联心电,也是为了提供与心脏功能障碍有关的诊断信息而设计的,传统上只能通过使用心脏成像来获得。MyoVista®还可以在同一测试中提供常规的心电信息。商业模式包括使用MyoVista®设备和每项测试的消耗品,预计将是“剃刀刀片”,因为MyoVista®使用的电极是心脏科学公司的专利,每进行一次测试都需要新的电极。
欲了解更多信息,请访问:Twitter:@HeartSciences
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
安全港声明
本公告包含符合1933年《证券法》第27A节和1934年《证券交易法》第21E节的前瞻性陈述。这些前瞻性陈述是根据“1995年私人证券诉讼改革法”中的“安全港”条款作出的,与公司未来的财务和经营业绩有关。除对历史事实的陈述外,本文中包括的所有陈述都是“前瞻性陈述”,其中包括关于心脏科学公司的信念和期望的陈述。这些陈述基于目前的预期、假设和不确定性,这些不确定性涉及对未来经济、竞争和市场状况以及未来商业决策的判断,所有这些都很难或不可能准确预测,而且许多都不是公司所能控制的。这些前瞻性陈述中反映的预期涉及重大假设、风险和不确定因素,这些预期可能被证明是不正确的。投资者不应过分依赖这些前瞻性陈述,这些陈述仅反映了本新闻稿发布之日的情况。潜在的风险和不确定因素包括但不限于心脏科学公司在提交给美国证券交易委员会的文件中讨论的风险,这些文件的网址是www.sec.gov。除证券法规定外,公司不承担更新这些前瞻性陈述的责任。
For investor and media inquiries, please contact:
Investor Relations:
Crescendo Communications, LLC
Phone: (212) 671-1021
Email: HSCS@crescendo-ir.com
投资者和媒体查询,请联系:
投资者关系:
Cresendo Communications,LLC
电话:(212)671-1021
电子邮件:hscs@cresendo-ir.com
Company:
Gene Gephart
Phone: +1-737-414-9213 (US)
Email: investorrelations@heartsciences.com
公司:
吉恩·格法特
电话:+1-737-414-9213(美国)
电子邮件:邮箱:Investorrelations.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧